The Mesalamine Market is expected to register a CAGR of 4% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Mesalamine Market report covers segmental analysis by Dosage From (Capsule, Tablets); Application (Ulcerative Colitis, Crohn's disease, Other Inflammatory Diseases), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Mesalamine Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Mesalamine Market Segmentation
Dosage From- Capsule
- Tablets
- Ulcerative Colitis
- Crohn's disease
- Other Inflammatory Diseases
Strategic Insights
Mesalamine Market Growth Drivers- Rising Prevalence of Inflammatory Bowel Diseases (IBD): The driving factor in the market of Mesalamine is the high rate of global prevalence of inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. These chronic conditions must be managed better by efficient treatments such as Mesalamine, which exhibits anti-inflammatory activities. Mesalamine is given for symptom management and to sustain remission in patients suffering from IBD, hence raising the demand for it.
- Growing Awareness and Early Diagnosis of IBD: The enhancements in healthcare accessibility and diagnosis technologies have contributed to an earlier diagnosis of IBD. Better awareness about diseases like ulcerative colitis leads to giving medicines such as Mesalamine in the beginning stages of the disease when its entire potential is not yet achieved. This increasing knowledge about IBD and available treatments creates an expanded market for Mesalamine.
- Increasing Demand for Oral and Topical Mesalamine Formulations: The increased demand for oral and topical preparations is the impetus for the Mesalamine market. Oral tablets and controlled-release formulations have become the most popular ones in patients suffering from conditions requiring long-term treatment. Besides, for local therapy of the disease, topical treatment in the form of enemas and suppositories is used routinely, which is causing an increased demand for Mesalamine products.
- Development of Combination Therapies with Mesalamine: Many combination therapies are predicted within the near future and Mesalamine is going to serve as a coformulation agent or used together with other biological agents or immunosuppressors. Thus, Mesalamine may also be prescribed using combination therapy as classes of drugs under biologics or Janus kinase inhibitors with a chance of improvement on clinical efficacy. Disease management, in general, may have an upward trend concerning more comprehensive concepts, and hence, this opens larger market sizes for Mesalamine products.
- Expansion of Mesalamine Applications Beyond IBD: Even though Mesalamine is primarily marketed to treat IBD, future market growth will be rooted in research done into other possible uses of the drug. The latest evidence shows that Mesalamine may have use in IBS and in certain forms of colorectal cancer. Wider applications of Mesalamine can create greater demand and make this medication a versatile treatment in gastroenterology medicine.
- Rise of Digital Health Solutions for IBD Management: Management of IBDs will most definitely transform the mesalamine market through digital health solutions. Smartphone Apps, telemedicine, and monitoring patients remotely would rapidly emerge into a vital elements of chronic management, like management of IBD. They may facilitate tracking patients' response so that better maintenance of Mesalamine therapy takes place in patient. Increased uptake of digital solutions in the care of patients would enhance engagement and management of treatment and, thus support the market for Mesalamine.
- Expansion of Mesalamine in Co-Treatment with Biologics: The potential for such Mesalamine products opens as biologic therapies are continuously being prescribed to patients suffering from moderate to severe IBD. Adding the use of Mesalamine can be extremely useful in conjunction with other biologics so that not only a therapeutic response is met, but recurrence rates are further diminished and prolonged remissions are maximized. This opportunity is specifically valuable in an increasing market in biologics; it's an opportunity where the older or traditional treatments find synergy with these newer, modern treatments.
- Focus on Maintenance Therapy for Long-Term Remission: A trend towards more long-term management of IBD offers a very major opportunity within maintenance therapy in Mesalamine. Mesalamine is one of the best drugs for maintenance therapy to keep patients suffering from IBD in remission long after the symptoms have been controlled. The emerging need for chronic therapies that prevent flare-ups and enhance quality of life greatly favors this drug. There is long-term market potential, as these IBD patients need to be treated continually.
- Increased Consumer Focus on Digestive Health: With increasing knowledge of global consumerism about digestive health, Mesalamine has good potential as greater numbers of patients are now consulting preventive care methods and managing diseases of the Gastrointestinal region at an initial stage. As doctors prescribe Mesalamine to a large number of IBD patients, growing knowledge about digestive health will probably increase awareness about the potential use of this medicine in keeping healthy intestines and managing related conditions. This shift in consumer behavior, therefore, provides more opportunities for Mesalamine towards a wider scope of consumers beyond IBD patients.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Mesalamine Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Mesalamine Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Mesalamine Market is expected to register a CAGR of 4% from 2025-2031.
The major factors impacting the Mesalamine Market are: Rising Prevalence of Inflammatory Bowel Diseases (IBD), Growing Awareness and Early Diagnosis of IBD and Increasing Demand for Oral and Topical Mesalamine Formulations
Key future trends in this market are - Development of Combination Therapies with Mesalamine, Expansion of Mesalamine Applications Beyond IBD and Rise of Digital Health Solutions for IBD Management
Key companies in this market are: Mylan N.V., Teva Pharmaceuticals, Ferring B.V., Allergan, Bausch Health Companies Inc., Zydus Cadila, COSMO PHARMACEUTICALS, Tillotts Pharma AG, Shire plc, Pfizer
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Mesalamine Market - By Dosage From
1.3.2 Mesalamine Market - By Application
1.3.3 Mesalamine Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MESALAMINE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MESALAMINE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. MESALAMINE MARKET - GLOBAL MARKET ANALYSIS
6.1. MESALAMINE - GLOBAL MARKET OVERVIEW
6.2. MESALAMINE - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. MESALAMINE MARKET - REVENUE AND FORECASTS TO 2028 - DOSAGE FROM
7.1. OVERVIEW
7.2. DOSAGE FROM MARKET FORECASTS AND ANALYSIS
7.3. CAPSULE
7.3.1. Overview
7.3.2. Capsule Market Forecast and Analysis
7.4. TABLETS
7.4.1. Overview
7.4.2. Tablets Market Forecast and Analysis
8. MESALAMINE MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ULCERATIVE COLITIS
8.3.1. Overview
8.3.2. Ulcerative Colitis Market Forecast and Analysis
8.4. CROHN'S DISEASE
8.4.1. Overview
8.4.2. Crohn's disease Market Forecast and Analysis
8.5. OTHER INFLAMMATORY DISEASES
8.5.1. Overview
8.5.2. Other Inflammatory Diseases Market Forecast and Analysis
9. MESALAMINE MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Mesalamine Market Overview
9.1.2 North America Mesalamine Market Forecasts and Analysis
9.1.3 North America Mesalamine Market Forecasts and Analysis - By Dosage From
9.1.4 North America Mesalamine Market Forecasts and Analysis - By Application
9.1.5 North America Mesalamine Market Forecasts and Analysis - By Countries
9.1.5.1 United States Mesalamine Market
9.1.5.1.1 United States Mesalamine Market by Dosage From
9.1.5.1.2 United States Mesalamine Market by Application
9.1.5.2 Canada Mesalamine Market
9.1.5.2.1 Canada Mesalamine Market by Dosage From
9.1.5.2.2 Canada Mesalamine Market by Application
9.1.5.3 Mexico Mesalamine Market
9.1.5.3.1 Mexico Mesalamine Market by Dosage From
9.1.5.3.2 Mexico Mesalamine Market by Application
9.2. EUROPE
9.2.1 Europe Mesalamine Market Overview
9.2.2 Europe Mesalamine Market Forecasts and Analysis
9.2.3 Europe Mesalamine Market Forecasts and Analysis - By Dosage From
9.2.4 Europe Mesalamine Market Forecasts and Analysis - By Application
9.2.5 Europe Mesalamine Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Mesalamine Market
9.2.5.1.1 Germany Mesalamine Market by Dosage From
9.2.5.1.2 Germany Mesalamine Market by Application
9.2.5.2 France Mesalamine Market
9.2.5.2.1 France Mesalamine Market by Dosage From
9.2.5.2.2 France Mesalamine Market by Application
9.2.5.3 Italy Mesalamine Market
9.2.5.3.1 Italy Mesalamine Market by Dosage From
9.2.5.3.2 Italy Mesalamine Market by Application
9.2.5.4 Spain Mesalamine Market
9.2.5.4.1 Spain Mesalamine Market by Dosage From
9.2.5.4.2 Spain Mesalamine Market by Application
9.2.5.5 United Kingdom Mesalamine Market
9.2.5.5.1 United Kingdom Mesalamine Market by Dosage From
9.2.5.5.2 United Kingdom Mesalamine Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Mesalamine Market Overview
9.3.2 Asia-Pacific Mesalamine Market Forecasts and Analysis
9.3.3 Asia-Pacific Mesalamine Market Forecasts and Analysis - By Dosage From
9.3.4 Asia-Pacific Mesalamine Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Mesalamine Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Mesalamine Market
9.3.5.1.1 Australia Mesalamine Market by Dosage From
9.3.5.1.2 Australia Mesalamine Market by Application
9.3.5.2 China Mesalamine Market
9.3.5.2.1 China Mesalamine Market by Dosage From
9.3.5.2.2 China Mesalamine Market by Application
9.3.5.3 India Mesalamine Market
9.3.5.3.1 India Mesalamine Market by Dosage From
9.3.5.3.2 India Mesalamine Market by Application
9.3.5.4 Japan Mesalamine Market
9.3.5.4.1 Japan Mesalamine Market by Dosage From
9.3.5.4.2 Japan Mesalamine Market by Application
9.3.5.5 South Korea Mesalamine Market
9.3.5.5.1 South Korea Mesalamine Market by Dosage From
9.3.5.5.2 South Korea Mesalamine Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Mesalamine Market Overview
9.4.2 Middle East and Africa Mesalamine Market Forecasts and Analysis
9.4.3 Middle East and Africa Mesalamine Market Forecasts and Analysis - By Dosage From
9.4.4 Middle East and Africa Mesalamine Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Mesalamine Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Mesalamine Market
9.4.5.1.1 South Africa Mesalamine Market by Dosage From
9.4.5.1.2 South Africa Mesalamine Market by Application
9.4.5.2 Saudi Arabia Mesalamine Market
9.4.5.2.1 Saudi Arabia Mesalamine Market by Dosage From
9.4.5.2.2 Saudi Arabia Mesalamine Market by Application
9.4.5.3 U.A.E Mesalamine Market
9.4.5.3.1 U.A.E Mesalamine Market by Dosage From
9.4.5.3.2 U.A.E Mesalamine Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Mesalamine Market Overview
9.5.2 South and Central America Mesalamine Market Forecasts and Analysis
9.5.3 South and Central America Mesalamine Market Forecasts and Analysis - By Dosage From
9.5.4 South and Central America Mesalamine Market Forecasts and Analysis - By Application
9.5.5 South and Central America Mesalamine Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Mesalamine Market
9.5.5.1.1 Brazil Mesalamine Market by Dosage From
9.5.5.1.2 Brazil Mesalamine Market by Application
9.5.5.2 Argentina Mesalamine Market
9.5.5.2.1 Argentina Mesalamine Market by Dosage From
9.5.5.2.2 Argentina Mesalamine Market by Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. MESALAMINE MARKET, KEY COMPANY PROFILES
11.1. MYLAN N.V.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. TEVA PHARMACEUTICALS
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. FERRING B.V.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ALLERGAN
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BAUSCH HEALTH COMPANIES INC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ZYDUS CADILA
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. COSMO PHARMACEUTICALS
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. TILLOTTS PHARMA AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SHIRE PLC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. PFIZER
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Mylan N.V.
2. Teva Pharmaceuticals
3. Ferring B.V.
4. Allergan
5. Bausch Health Companies Inc
6. Zydus Cadila
7. COSMO PHARMACEUTICALS
8. Tillotts Pharma AG
9. Shire plc
10. Pfizer
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For